SecBot SecBot
DEF 14A ·Filed Oct 21, 2026

RZLT

Rezolute, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed5d 16h ago SEC0001104659-26-117868
Definitive proxy statement
Actionable Insight • Neutral

The share increase proposal is the key item — passage enables future equity financing but creates overhang. Monitor the say-on-pay vote percentage (if disclosed post-meeting) as a gauge of investor sentiment on compensation, particularly the new gross-up provisions. The upcoming upLIFT topline data (expected before year-end 2026) is the primary binary catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+1d
RZLT ▼ -0.13% at T+1d
NEUTRAL call -0.13% · α vs SPY +0.39% · entry $3.86 → $3.86
Next anchor: T+5d in 22h
Entry = T+0 close
Oct 21, 2026
via day close
T+1d
-0.13%
call -0.13% · α +0.39%
$3.86
settled 5d ago
T+5d
Pending
in 22h
T+20d
Pending
in 22d
T+60d
Pending
in 3mo

Price Chart

Loading chart...

Executive Summary

Rezolute filed its definitive proxy statement for the 2027 Annual Meeting, seeking shareholder approval for seven director nominees, ratification of Grant Thornton as auditor, an advisory say-on-pay vote, and a critical proposal to increase authorized common stock from 165 million to 225 million shares. The share increase is needed to provide flexibility for future financing and strategic transactions, as the company's cash burn rate ($77.6M net loss in FY2026) and cash runway ($107.8M at June 30, 2026) suggest a need for capital within the next 12-18 months. The proxy also discloses CEO Nevan Elam's total FY2026 compensation of $5.71M, including $4.58M in equity awards, and a new 'gross-up' parachute payment provision added to all NEO employment agreements on October 17, 2025.

Key Facts

  • Annual Meeting scheduled for December 2, 2026; record date October 5, 2026; 96,728,913 shares outstanding
  • Proposal 4 seeks to increase authorized common stock from 165M to 225M shares (36% increase) for future financing and strategic flexibility
  • CEO Nevan Elam total FY2026 compensation: $5,711,410 (salary $655K, bonus $450,912, stock awards $3.22M, option awards $1.36M)
  • Net loss FY2026: $77.6M vs $74.4M in FY2025; cash and investments $107.8M vs $167.9M a year ago
  • Phase 3 sunRIZE study in congenital HI did not meet primary endpoint; data under FDA review
  • Phase 3 upLIFT study in tumor HI ongoing; topline results expected before end of 2026
  • All NEO employment agreements amended on October 17, 2025 to include Section 280G excise tax gross-up payments
  • No shareholder proposals on the ballot; no contested director elections
  • Last year's say-on-pay approval rate not disclosed in filing
  • Top 5% holders: Federated Hermes (16.49%), RA Capital (9.76%), Handok (8.71%), BlackRock (7.98%), Opaleye (6.51%)

Financial Impact

Authorized share increase of 60M shares (36% dilution potential) for future capital raises; cash burn rate ~$77.6M/year with $107.8M cash runway of ~16-17 months

dilutioncash runwayauthorized shares

Risk Factors

  • Share increase dilutes existing holders by up to 36% if all new shares are issued
  • Phase 3 sunRIZE study failure in congenital HI creates regulatory uncertainty for ersodetug
  • Cash burn rate of ~$77.6M/year with $107.8M cash implies need for financing within ~16 months
  • CEO compensation of $5.71M with gross-up provisions may attract negative say-on-pay votes

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
DEF 14A Filing (Primary)0001104659-26-117868
Document: 0001104659-26-117868-index.html0001104659-26-117868
Document: 0001104659-26-117868.txt0001104659-26-117868
13 reports for RZLT
Performance horizon
80% Hit rate @ T+20 4 of 5 directional calls Went positive at some point 5 of 5 best @ T+60▲ +26.00%Jun 2, 2026
Filters
Rows
Reports for RZLT — sortable, filterable
TypeNow
Oct 21, 2026
5d ago
DEF 14A
NEUTRAL ★ 5/10
$3.86awaiting T+20—$3.89 (+0.78%)
Oct 14, 2026
12d ago
8-K
NEUTRAL ★ 5/10
$3.90awaiting T+20—$3.89 (−0.26%)
Oct 5, 2026
22d ago
8-K
MIXED ★ 6/10
$4.33awaiting T+20—$3.89 (−10.16%)
Sep 24, 2026
4w ago
8-K
BEARISH ★ 6/10
$3.90 $3.86▲ +1.15%▼ −0.32%$3.89 (+0.26%)
Sep 24, 2026
4w ago
Press Release
BEARISH ★ 6/10
$3.90 $3.86▲ +1.15%▼ −0.32%$3.89 (+0.26%)
Jul 21, 2026
14w ago
Press Release
NEUTRAL ★ 2/10
$5.09 $4.66▼ −8.45%▼ −11.01%$3.89 (−23.58%)
Jun 11, 2026
19w ago
Institutional Cluster
NEUTRAL ★ 2/10
$3.86 $5.13▲ +32.90%▲ +31.01%$3.89 (+0.78%)
Jun 4, 2026
20w ago
Press Release
NEUTRAL ★ 3/10
$4.51 $4.91▲ +8.87%▲ +10.24%$3.89 (−13.75%)
Jun 2, 2026
21w ago
8-K
BULLISH ★ 7/10
$4.00 $4.95▲ +23.75%▲ +25.32%$3.89 (−2.75%)
May 12, 2026
23w ago
8-K
NEUTRAL ★ 5/10
$3.33 $3.86▲ +15.92%▲ +16.53%$3.89 (+16.82%)
Showing 10 of 13

US Market Status

Market Open — Closes in 6h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 21, 2026